secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001493152-22-035311
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma announces departure of President of R&D and CMO Gregory Berk
-------------------------------------------------------------------------

- Dr. Gregory Berk no longer employed as President of R&D and Chief Medical Officer effective December 8, 2022.
- No successor or interim replacement named in the filing.
- Departure comes as GT Biopharma (GTBP) advances its cancer immunotherapy pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315222035311/0001493152-22-035311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315222035311/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer